What Nbryo does

Nbryo is an Australian agri-biotech company developing and commercialising an integrated platform for scalable bovine in vitro fertilisation (IVF) and embryo transfer, aimed at cattle seedstock producers, commercial beef operations, and dairy farmers. Founded from 15 years of embryo transfer and genomics research at the Nindooinbah breeding property in Queensland, the company opened its first state-of-the-art Bovine IVF laboratory and headquarters in Eight Mile Plains, Brisbane in October 2023, and has since established two purpose-built Donor Centres in Toogoolawah and Dalby for producers with fewer than 25 donors. The platform combines four integrated steps: genetic selection (including sexing and genomic pre-implantation screening), embryo production via proprietary in vitro production (IVP) culture plus the patented embryo multiplication technology launched in November 2025, a simplified embryo transfer device targeted for October 2026 release, and an AI/ML analytics layer for supply chain forecasting and traceability. Its headline technical claim is condensing seven years of conventional genetic improvement into a seven-day IVP cycle, with multiplication technology delivering twice the embryos using half the donors and half the semen.

The business model combines fee-for-service revenue (OPU, embryo production, fresh and frozen embryo transfer delivered on-farm or via Donor Centres) with unit-priced embryo sales at an introductory AUD $150 per Grade 1 embryo, reduced from AUD $180 following multiplication Stage 1. Go-to-market is sales-led and direct, supported by an in-house field services team, a Tech Ambassador Program of early-adopter reference customers, and an industry partnership with the Australian Wagyu Association. Marketing channels include the proprietary 'Leading the Herd' podcast, an extensive knowledge base, agricultural media coverage, and field-day events. Revenue is not publicly disclosed.

The company is privately held and venture-backed, having raised over AUD $22 million in equity since 2024 across a $10M first close (October 2025) and an $8M second close (March 2026 anchored by USD $4M from the Gates Foundation), plus over AUD $18 million in grant funding from the Gates Foundation, Meat & Livestock Australia, and Australian state and federal programs. Key equity investors include Tenacious Ventures, AgriZeroNZ, Queensland Investment Corporation, Mandalay Venture Partners, and the Murdoch family. Leadership comprises CEO Paul Niven (appointed January 2025), Executive Chairman Dr Gerard Davis, and Co-Founders Euan Murdoch and Nick Cameron, supported by a team of approximately 20 spanning embryology, research, operations, and commercial functions.

Name

Nbryo

Legal name

Nbryo Pty Limited

Website

https://nbryo.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Nbryo is an Australian agri-biotech company commercialising an integrated bovine IVF and embryo transfer platform that enables accelerated, affordable genetic improvement for seedstock, commercial beef, and dairy producers through patented embryo multiplication and bio-digital technologies.

Ownership category

akta.pro rank

Product category

Livestock Reproductive Biotechnology Services

NAICS

Support Activities for Animal Production (11521)

SIC

Agricultural Services (700), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Embryo Transfer (ET) & IVF Services (Superovulation, Flushing, Implantation) (AFACAEAB)

akta.pro secondary industry

Breeding Program Design & Genetic Consulting (Mating Plans, EPD/Index Selection) (AFACAEAD)

Keywords

• Bovine IVF services
• Embryo transfer technology
• Livestock genetic improvement
• Cattle breeding biotechnology
• Animal reproductive services

Headquarters

HQ city

Eight Mile Plains

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. IVF and Embryo Transfer Services: Nbryo provides commercial in vitro fertilisation (IVF) and embryo transfer (ET) services to cattle producers. Oocyte collection (OPU), embryo production, fresh or frozen embryo transfer, and associated laboratory services are offered as fee-for-service programs. Services are delivered on-farm or at Nbryo's Donor Centres.
2. Embryo Sales (Grade 1 Embryos): Nbryo produces and sells Grade 1 embryos at AUD $150 (introductory price, reduced from $180). Embryo multiplication technology enables higher embryo yields, reducing cost per embryo. Future genomic screening will allow selection of embryos with specific traits before transfer.
3. Equity Capital Raising: Nbryo has raised over AUD $22 million in equity since 2024, including a $10 million first close (October 2025) and an $8 million second close (March 2026). The Gates Foundation contributed USD $4 million. SAFE note conversion of $12.3 million brought total raised since 2024 to over $22 million. Additionally, over $18 million in grant funding has been received from Gates Foundation, Meat & Livestock Australia, and government programs.
4. Equity Investment (Seed Round): Nbryo has an open Seed Round for new equity investors, managed by Investor Relations contact Nick Bonifant. The company is raising capital to fund technology development, commercial expansion, and the October 2026 product launch.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Nbryo provides commercial bovine in vitro fertilisation (IVF), ovum pick-up (OPU), and embryo transfer (ET) services to cattle producers, producing and selling Grade 1 embryos at AUD $150 per unit. The offering is anchored by a patented Embryo Multiplication Technology that doubles embryo yield while improving Embryo Development Rates, and is delivered through on-farm field services, two purpose-built Donor Centres in Queensland, and a development pipeline that includes genomic pre-implantation screening, a proprietary embryo transfer device, and AI/ML-enabled herd analytics.

Product overview

Nbryo is developing and commercialising an integrated technology platform for bovine IVF that enables accessible, accelerated, and affordable genetic improvement through in vitro production of embryos. The platform combines eight key services across the reproductive technology workflow: Breeding Objective Design (in development), Oocyte Collection Services, Embryo Production, Genomic Screening (coming soon), Embryo Multiplication Technology (launched November 2025), Embryo Preservation (in development), Embryo Transfer Technology with a device planned for October 2026 release, and Analysis/Data Services. Using advanced bio-digital and robotic technologies, the platform enables 7 years of genetic improvement to be achieved within a 7-day in vitro embryo production cycle. Nbryo also operates Donor Centre facilities in Toogoolawah and Dalby, Queensland.

Differentiator

Problem solved

Functional benefit

Products and services

• Commercial IVF and Embryo Transfer Services Fee-for-service commercial bovine IVF program delivered through Nbryo's field services team and laboratory. Includes ovum pick-up (OPU) on-farm or at collection centres, fertilisation and embryo culture in the lab, and fresh or frozen embryo transfer using fixed-time embryo transfer (FTET) protocols. Optional FSH stimulation is available to increase oocyte quality and Embryo Development Rates. OPU can be performed as frequently as fortnightly. Services are delivered on-farm for larger producers and via Donor Centres for those with fewer than 25 donors.
• Nbryo Donor Centres Two purpose-built facilities in Toogoolawah and Dalby, Queensland, that provide structured, donor-focused IVF programs integrating donor management, OPU, fertilisation, embryo culture, and transfer planning. Designed for producers with fewer than 25 donors who cannot achieve economies of scale with on-farm infrastructure, making advanced reproductive technology accessible, practical, and affordable.
• Embryo Multiplication Technology A patented biological process that naturally multiplies embryo yield while improving Embryo Development Rates. Not cloning or embryo splitting, the technology produces more Grade 1 embryos at lower cost. Enabled Grade 1 embryo introductory pricing of AUD $150 (reduced from AUD $180), with further cost reductions expected as the platform scales.
• Embryo Transfer Device A proprietary device under development that will enable semi-skilled operators such as AI technicians to perform embryo transfers into recipient cows without requiring a specialist ET vet or epidural. Designed to lower skill barriers, reduce cost, and address the critical shortage of skilled embryo transfer technicians in the cattle industry.
• Genomic Pre-implantation Screening Technology to select or de-select embryos in the dish based on genomic traits including gender, horn/poll status, recessive genetic conditions, coat colour, and performance-oriented SNP panels. Enables selection of embryos before implantation rather than waiting for calf birth to assess traits, supporting faster structural herd change and direct selection for methane reduction, productivity, and welfare traits.
• Grade 1 Embryos Nbryo produces and sells Grade 1 embryos at an introductory price of AUD $150 per embryo, reduced from AUD $180 through Stage 1 of embryo multiplication technology. Embryo multiplication enables higher yields and lower per-embryo cost. Future genomic screening will allow selection of embryos with specific traits before transfer.

Quantifiable outcome

• 7 years of genetic improvement achievable in a 7-day in vitro embryo production cycle, compared to existing systems that achieve 10% trait improvement over 7 years at best
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

13 partnerships are on record, tiered key, research, strategic, pilot and foundational.

• Australian Wagyu Association (AWA)keyStrategic or Co-development Partner · 1 March 2024Corporate business partnership recognising alignment between Nbryo and AWA in advancing the Australian livestock industry. Partnership provides market access and co-marketing opportunities within the Australian Wagyu breeder community. AWA members benefit from preferential access to Nbryo's IVF services and technology platform.
• University of SydneyresearchStrategic or Co-development PartnerResearch partner contributing scientific expertise. Associate Professor Margot Day serves as Nbryo's Lead Scientist from the University of Sydney, playing a key role in developing the embryo multiplication technology.
• University of Queensland (UQ)researchStrategic or Co-development PartnerResearch partner from the Nbryo/Nindooinbah program origins. Euan Murdoch served as Adjunct Professor at UQ's Australian Institute of Bioengineering and Nanotechnology and member of UQ's Institute of Molecular Biosciences Commercialisation Board.
• RMIT UniversityresearchStrategic or Co-development PartnerResearch partner in Nbryo's multi-disciplinary product development network spanning biology, genomics, engineering, biosensors, and data science. Research partner Crispin from RMIT is referenced in team activities.
• University of MichiganresearchStrategic or Co-development PartnerInternational research partner in Nbryo's network across Australia, New Zealand, India, Kenya, and the USA.
• International Livestock Research Institute (ILRI)strategicStrategic or Co-development PartnerILRI Director General Professor Appolinaire Djikeng serves on Nbryo's Scientific Advisory Committee. ILRI focuses on challenges facing smallholder production systems in Sub-Saharan Africa, where Nbryo plans to deploy its platform to address food security and climate challenges. Collaboration helps plan Nbryo platform development for developing country contexts.
• Jemalong Pastoral CompanypilotGTM or Marketing PartnerQueensland Wagyu operation participating in Nbryo's Tech Ambassador Program as an early adopter of Nbryo's IVF technology. The Bachmann family (Maree and Russell) completed two OPU sessions producing 62 embryos implanted into recipients. They serve as reference customers and advocates, providing feedback on early-stage technology.
• In2BeingresearchTechnology or IntegrationPartner company in Nbryo's research network contributing to platform development.
• Expedite Animal HealthresearchTechnology or IntegrationPartner company in Nbryo's research network contributing to the development of reproductive biotechnology.
• Global Health Labs (GHLabs)researchStrategic or Co-development PartnerPartner institution in Nbryo's international research network contributing to platform development for livestock genetic improvement.
• New Zealand Agricultural Greenhouse Gas Research CentreresearchStrategic or Co-development PartnerPartner organisation in Nbryo's research network with focus on agricultural greenhouse gas mitigation, directly aligned with Nbryo's methane reduction technology goals.
• Tropical Animal Genetics (TAG)researchTechnology or IntegrationPartner company in Nbryo's research and commercial development network, contributing expertise in tropical animal genetics.
• NindooinbahfoundationalStrategic or Co-development PartnerQueensland beef breeding property and origin of Nbryo's technology. 15 years of research into embryo transfer and genomics at Nindooinbah under Nick Cameron's management. Euan and Kaye Murdoch's breeding property was the testbed for the platform's development. Commercially focused production of elite genetic progeny continues at Nindooinbah.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• CRV: International cattle genetics cooperative with strong dairy and beef breeding programs and embryo services. Comparable to Nbryo as a genetics improvement platform serving commercial and seedstock producers globally.
• Semex: Canadian bovine genetics cooperative offering AI, genomic testing and increasingly IVF/ET services. Comparable as a global genetics improvement company serving dairy and beef customers with an integrated technology stack.
• ABS Global (Genus plc): Largest global bovine genetics business within Genus plc, with established embryo transfer, sexed semen, and IVF/IVP offerings. Competes across the same customer workflows but at materially greater scale and geographic reach.
• Cogent Breeding: UK-based bovine genetics business with sexed semen and IVF capabilities serving dairy and beef producers. Comparable as an integrated genetics and embryo services provider targeting commercial herds.
• Livestock Improvement Corporation (LIC): New Zealand dairy genetics cooperative where Nbryo Director Emma Blott previously held senior executive roles. Comparable as a large-scale, technology-enabled bovine genetics and reproduction services provider, particularly in dairy.

Direct peers

• ST Genetics: Global bovine genetics provider with significant IVF/IVP services and sexed semen capabilities. Competes with Nbryo for elite-donor IVF programs and sexed embryo selection in beef and dairy.
• Vytelle: Technology-driven bovine IVF company combining reproductive biology with a proprietary data platform to multiply elite genetics, closely aligned with Nbryo's integrated bio-digital platform thesis and donor-centric IVF model.
• Alta Genetics: Global bovine genetics company where Nbryo CEO Paul Niven previously served as VP of International Sales. Direct comparable in elite dairy and beef genetics, AI services, and increasingly IVP/embryo offerings.
• Trans Ova Genetics: US-based leader in bovine IVF and embryo transfer services, offering OPU, IVP, fresh/frozen embryo transfer and recipient management. Directly comparable to Nbryo's service offering and customer base of seedstock and commercial cattle producers.

Regional players

• InVitro Brazil: Brazil-based bovine IVF and embryo transfer services company. Comparable as a regional IVF/ET services provider focused on tropical cattle production, but operating in Latin America rather than Australia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeopen.spotify.com/show/2IFmXqSOyQu9LymrP0pCnW
• LinkedInlinkedin.com/company/nbryo
• Xx.com/nbryoaus

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nbryo